AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A compound of Formula (**I**):



(I)

wherein:

R_1 is H or C_{1-8} alkyl;

R_2 is C_{2-4} alkenyl, C_{1-4} alkyl or C_{1-4} haloalkyl; and

R_3, R_4, R_5, R_6 and R_7 are each independently H, C_{1-4} acyl, C_{1-4} acyloxy, C_{1-4} acylthioxy, C_{2-4} alkenyl, C_{1-4} alkoxy, C_{1-4} alkyl, C_{1-4} alkylcarboxamido, C_{1-4} alkylsulfinyl, ~~C_{1-4}-alkylsulfonamide,~~ C_{1-4} alkylsulfonyl, C_{1-4} alkylthio, amino, C_{1-4} alkylamino, carbo-C_{1-4}-alkoxy, carboxamide, cyano, C_{2-6} dialkylamino, C_{1-4} haloalkoxy, C_{1-4} haloalkyl, C_{1-4} haloalkylsulfinyl, C_{1-4} haloalkylsulfonyl, C_{1-4} haloalkylthio, halogen, hydroxyl, phenyl, and thiol; or

a pharmaceutically acceptable salt, hydrate and solvate thereof;

provided that the compound is not 1-(4-Chloro-phenyl)-2-methyl-piperazine; 1-(3,5-Difluoro-phenyl)-2-methyl-piperazine; 2-Methyl-1-(2-methylsulfanyl-phenyl)-piperazine; 4-Amino-3-fluoro-2-(2-methyl-piperazin-1-yl)-5-nitro-benzonitrile; 2-Methyl-1-phenyl-piperazine; 4-(2-Isopropyl-piperazin-1-yl)-2-trifluoromethyl-benzonitrile; 4-(2-Ethyl-piperazin-1-yl)-2-trifluoromethyl-benzonitrile; 4-(2-Methyl-piperazin-1-yl)-2-trifluoromethyl-benzonitrile; 1-(3-Chloro-phenyl)-2-methyl-piperazine; 2-Methyl-1-m-tolyl-piperazine; 4-(2-Methyl-piperazin-1-yl)-benzamide; 1-(2-Fluoro-phenyl)-2-methyl-piperazine; 4-(2-Methyl-piperazin-1-yl)-phenol; 1-(3-Methoxy-

phenyl)-2-methyl-piperazine; 2-Methyl-1-(3-trifluoromethyl-phenyl)-piperazine; 1-(4-Methoxy-phenyl)-2-methyl-piperazine; 2-Methyl-1-p-tolyl-piperazine; 2,4-Dimethyl-1-phenyl-piperazine; 4-Chloro-5-(4-ethyl-2-methyl-piperazin-1-yl)-benzene-1,2-diamine; 4-Chloro-5-(4-ethyl-2-methyl-piperazin-1-yl)-2-nitro-phenylamine; 5-(4-Ethyl-2-methyl-piperazin-1-yl)-2-nitro-4-trifluoromethyl-phenylamine; and 5-(4-Ethyl-2-methyl-piperazin-1-yl)-4-methyl-2-nitro-phenylamine.

2. (Original) The compound according to claim 1 wherein R_1 is H.

3. (Original) The compound according to claim 1 wherein R_1 is C_{1-8} alkyl.

4-8. (Canceled).

9. (Previously presented) The compound according to claim 1 wherein R_2 is C_{2-4} alkenyl.

10. (Canceled).

11. (Previously presented) The compound according to claim 1 wherein R_2 is C_{1-4} alkyl.

12. (Previously presented) The compound according to claim 1 wherein R_2 is methyl.

13-16. (Canceled).

17. (Previously presented) The compound according to claim 1 wherein R_3, R_4, R_5, R_6 and R_7 are each independently selected from the group consisting of H, C_{1-4} alkoxy, C_{1-4} alkyl, cyano, C_{1-4} haloalkoxy, C_{1-4} haloalkyl and halogen.

18. (Canceled).

19. (Original) The compound according to claim 17 wherein R_3, R_4, R_5, R_6 and R_7 are each independently selected from the group consisting of H, C_{1-4} haloalkoxy, C_{1-4} haloalkyl and halogen.

20. (Original) The compound according to claim 17 wherein R_3, R_4, R_5, R_6 and R_7 are each independently selected from the group consisting of H, CH_3, CH_2CH_3, $CH(CH_3)_2$, cyano, OCF_3, CF_3, F, Cl and Br.

21. (Original) The compound according to claim 17 wherein R_3, R_4, R_5, R_6 and R_7 are each independently selected from the group consisting of H, CF_3, F, Cl and Br.

22. (Previously presented) The compound according to claim 1 wherein R_3 is H or F.

23. (Previously presented) The compound according to claim 1 wherein R_4 is selected from the group consisting of H, cyano, F, Cl and Br.

24. (Previously presented) The compound according to claim 1 wherein R_5 is selected from the group consisting of H, CH_3, $CH(CH_3)_2$, OCF_3, CF_3, F, Cl and Br.

25. (Previously presented) The compound according to claim 1 wherein R_6 is selected from the group consisting of H, F, Cl and Br.

26. (Previously presented) The compound according to claim 1 wherein R_7 is selected from the group consisting of H, CH_3, F, Cl and Br.

27. (Original) The compound of claim 1 selected from the group consisting of:

1-(2,3-Difluoro-phenyl)-2-ethyl-piperazine;

1-(3-Fluoro-phenyl)-2-ethyl-piperazine;

1-(4-Fluoro-phenyl)-2-ethyl-piperazine;

(R)-1-(3-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(3-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;

(S)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;

(R)-1-(3-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(3-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(4-Fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(4-Fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(3,4-Dichloro-phenyl)-2-methyl-piperazine;

(S)-1-(3,4-Dichloro-phenyl)-2-methyl-piperazine;

(R)-1-(3-Chloro-4-methyl-phenyl)-2-methyl-piperazine;

(S)-1-(3-Chloro-4-methyl-phenyl)-2-methyl-piperazine;

(R)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;

(S)-1-(3,4-Difluoro-phenyl)-2-methyl-piperazine;

(R)-1-(3,5-Dichloro-phenyl)-2-methyl-piperazine;

(S)-1-(3,5-Dichloro-phenyl)-2-methyl-piperazine;

(R)-1-(2,5-Difluoro-phenyl)-2-methyl-piperazine;

(S)-1-(2,5-Difluoro-phenyl)-2-methyl-piperazine;

(R)-1-(4-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(4-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(3-Chloro-2-methyl-phenyl)-2-methyl-piperazine;

(S)-1-(3-Chloro-2-methyl-phenyl)-2-methyl-piperazine;

(R)-1-(5-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(5-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(5-Chloro-2-methyl-phenyl)-2-methyl-piperazine;

(S)-1-(5-Chloro-2-methyl-phenyl)-2-methyl-piperazine;

1-(3-Chloro-4-fluoro-phenyl)-2-ethyl-piperazine;

1-(3-Chloro-phenyl)-2-ethyl-piperazine;

1-(4-Chloro-phenyl)-2-ethyl-piperazine;

1-(3,4-Difluoro-phenyl)-2-ethyl-piperazine and

(R)-1-(5-Chloro-2-fluoro-phenyl)-2-ethyl-piperazine;

or a pharmaceutically acceptable salt, hydrate and solvate thereof.

28. (Original) The compound of claim 1 selected from the group consisting of:

(R)-1-(2-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;

(S)-1-(2-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;

(R)-1-(4-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(4-Chloro-2-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(3-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(3-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(3-Fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(3-Fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(2-Fluoro-4-trifluoromethyl-phenyl)-2-methyl-piperazine;

(S)-1-(2-Fluoro-4-trifluoromethyl-phenyl)-2-methyl-piperazine;

(R)-1-(2-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(2-Chloro-3-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(2-Fluoro-5-methyl-phenyl)-2-methyl-piperazine;

(S)-1-(2-Fluoro-5-methyl-phenyl)-2-methyl-piperazine;

(R)-1-(4-Fluoro-biphenyl-3-yl)-2-methyl-piperazine;

(S)-1-(4-Fluoro-biphenyl-3-yl)-2-methyl-piperazine;

(R)-1-(2,5-Difluoro-4-methoxy-phenyl)-2-methyl-piperazine;

(S)-1-(2,5-Difluoro-4-methoxy-phenyl)-2-methyl-piperazine;

(R)-1-(2-Fluoro-4-methyl-phenyl)-2-methyl-piperazine;

(S)-1-(2-Fluoro-4-methyl-phenyl)-2-methyl-piperazine;

(R)-1-(2-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(2-Chloro-5-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(2-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;

(S)-1-(2-Chloro-4-fluoro-phenyl)-2-methyl-piperazine;

(R)-1-(2,4-Dichloro-phenyl)-2-methyl-piperazine;

(S)-1-(2,4-Dichloro-phenyl)-2-methyl-piperazine;

(R)-1-(2,5-Dichloro-phenyl)-2-methyl-piperazine;

(S)-1-(2,5-Dichloro-phenyl)-2-methyl-piperazine;

(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-piperazine;
(S)-1-(3,5-Bis-trifluoromethyl-phenyl)-2-methyl-piperazine;
(R)-1-(4-Fluoro-2-methyl-phenyl)-2-methyl-piperazine;
(S)-1-(4-Fluoro-2-methyl-phenyl)-2-methyl-piperazine;
(R)-1-(2-Chloro-phenyl)-2-methyl-piperazine;
(S)-1-(2-Chloro-phenyl)-2-methyl-piperazine;
(R)-1-(2,3-Dichloro-phenyl)-2-methyl-piperazine;
(R)-1-(2,3-Dichloro-phenyl)-2-methyl-piperazine;
(R)-1-(2,6-Dichloro-phenyl)-2-methyl-piperazine;
(R)-1-(2,6-Dichloro-phenyl)-2-methyl-piperazine;
(R)-1-(2-Chloro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;
(R)-1-(2-Chloro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;
(R)-2-Methyl-1-(4-trifluoromethyl-phenyl)-piperazine;
(S)-2-Methyl-1-(4-trifluoromethyl-phenyl)-piperazine;
(R)-1-(2-Fluoro-3-trifluoromethyl-phenyl)-2-methyl-piperazine;
(S)-1-(2-Fluoro-3-trifluoromethyl-phenyl)-2-methyl-piperazine;
(R)-1-(3-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;
(R)-1-(3-Fluoro-5-trifluoromethyl-phenyl)-2-methyl-piperazine;
(R)-1-(4-Chloro-3-trifluoromethyl-phenyl)-2-methyl-piperazine;
(S)-1-(4-Chloro-3-trifluoromethyl-phenyl)-2-methyl-piperazine; and
(R)-2,4-Dimethyl-1-(3-trifluoromethyl-phenyl)-piperazine;
or a pharmaceutically acceptable salt, hydrate and solvate thereof.

29. (Original) The compound of claim 1 selected from the group consisting of:
1-(2-Bromo-phenyl)-2-vinyl-piperazine;
1-(4-Chloro-phenyl)-2-vinyl-piperazine;
1-(3-Fluoro-phenyl)-2-vinyl-piperazine;
1-(3-Chloro-4-fluoro-phenyl)-2-vinyl-piperazine;
1-(3-Chloro-phenyl)-2-vinyl-piperazine;
1-(3-Bromo-phenyl)-2-vinyl-piperazine;
1-(3,5-Dichloro-phenyl)-2-vinyl-piperazine;

1-(2-Bromo-4-isopropyl-phenyl)-2-vinyl-piperazine;

1-(2-Bromo-4-trifluoromethoxy-phenyl)-2-vinyl-piperazine;

1-(2-Bromo-4-trifluoromethyl-phenyl)-2-vinyl-piperazine;

3-(2-Vinyl-piperazin-1-yl)-benzonitrile;

1-(3,5-Difluoro-phenyl)-2-vinyl-piperazine;

1-*o*-Tolyl-2-vinyl-piperazine and

1-(2,3-Difluoro-phenyl)-2-vinyl-piperazine;

or a pharmaceutically acceptable salt, hydrate and solvate thereof.

30. (Previously presented) The compound according to claim 1 wherein said compound is an *R* enantiomer.

31. (Previously presented) The compound according to claim 1 wherein said compound is an *S* enantiomer.

32. (Original) A pharmaceutical composition comprising a pharmaceutical acceptable carrier in combination with at least one compound according to Formula (**I**):



(I)

wherein:

R_1 is H or C_{1-8} alkyl;

R_2 is C_{2-4} alkenyl, C_{1-4} alkyl or C_{1-4} haloalkyl; and

R_3, R_4, R_5, R_6 and R_7 are each independently H, C_{1-4} acyl, C_{1-4} acyloxy, C_{1-4} acylthioxy, C_{2-4} alkenyl, C_{1-4} alkoxy, C_{1-4} alkyl, C_{1-4} alkylcarboxamido, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonamide, C_{1-4} alkylsulfonyl, C_{1-4} alkylthio, amino, C_{1-4} alkylamino, carbo-C_{1-4}-alkoxy, carboxamide, cyano, C_{2-6} dialkylamino, C_{1-4} haloalkoxy, C_{1-4} haloalkyl, C_{1-4}

haloalkylsulfinyl, C_{1-4} haloalkylsulfonyl, C_{1-4} haloalkylthio, halogen, hydroxyl, phenyl, and thiol; or

a pharmaceutically acceptable salt, hydrate and solvate thereof.

33. (Previously presented) A method of modulating a $5HT_{2C}$ receptor comprising contacting said receptor with a therapeutically effective amount of a compound as in claim 1.

34. (Original) The method according to claim 33 wherein said compound is an agonist of said receptor.

35. (Previously presented) A method of prophylaxis or treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus or sleep apnea comprising administering to an individual in need of such prophylaxis or treatment a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 32.

36. (Currently amended) The method according to claim 35 wherein the disorders of the central nervous system are selected the group consisting of depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, Alzheimer disease, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug addiction, ~~and~~ alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

37. (Original) The method according to claim 36 wherein the disorder of the central nervous system is obesity.

38. (Canceled).

39. (Original) The method according to claim 36 wherein the sexual dysfunction is Male erectile dysfunction.

40-44. (Canceled).

45. (Currently amended) The method according to claim 37 ~~or 39~~ wherein said individual is a human.

46. (Previously presented) A method of decreasing food intake of an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 32.

47. (Canceled).

48. (Previously presented) The method according to claim 46 wherein said individual is a human.

49. (Previously presented) A method of inducing satiety in an individual comprising administering to said individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 32.

50. (Canceled).

51. (Previously presented) The method according to claim 49 wherein said individual is a human.

52. (Previously presented) A method of controlling weight gain of an individual comprising administering to said individual suffering from weight control a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 32.

53. (Canceled).

54. (Previously presented) The method according to claim 52 wherein said individual is a human.

55-58. (Canceled).

59. (Previously presented) A method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and a pharmaceutically acceptable carrier.

60-78. (Canceled).

79. (Previously presented) The compound according to claim 1 wherein:

R_1 is H, methyl, ethyl, *n*-propyl, *iso*-propyl or *n*-butyl;

R_2 is a vinyl, methyl, ethyl, *n*-propyl, C_{1-4} haloalkyl or $-CF_3$;

R_3 is H or F;

R_4 is selected from the group consisting of H, cyano, F, Cl and Br;

R_5 is selected from the group consisting of H, CH_3, $CH(CH_3)_2$, OCF_3, CF_3, F, Cl and Br;

R_6 is selected from the group consisting of H, F, Cl and Br; and

R_7 is selected from the group consisting of H, CH_3, F, Cl and Br.

80. (Previously presented) A method of treating a $5HT_{2C}$ receptor associated disorder comprising administering to an individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutical composition according to claim 32.

81. (New) A method of treating obesity comprising administering to an individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutical composition according to claim 32.

82. (New) A method of treating depression comprising administering to an individual in need of such treatment an effective amount of a compound according to claim 1, or a pharmaceutical composition according to claim 32.

83. (New) The method according to claim 39 wherein said individual is a human.